Reason for request
Remains substantial in type 1 and type 2 diabetes.
Improvement in actual benefit
Given, on the one hand :
- the absence of a difference between insulin glargine, insulin detemir and NPH insulin in terms of the occurrence of severe hypoglycaemia and between insulin glargine and insulin detemir in terms of overall and nocturnal hypoglycaemia,
- the opinion of experts who do not recognise any benefit in their daily practice of using LANTUS compared with another long acting insulin analogue,
And, on the other hand,
the Transparency Committee cannot confirm the previously recognised benefit of LANTUS (minor IAB in terms of safety) in type 1 and type 2 diabetes.
Thus, the Committee considers that LANTUS (insulin glargine) does not provide an improvement in actual benefit (levelV, non-existent) in the management of adult or adolescent patients and children aged 2 and above with type 1 or type 2 diabetes.